CNSide Diagnostics Leadership Appointments

Plus Therapeutics Announces Key Leadership Appointments for CNSide Diagnostics, LLC We are excited to announce the appointment of Russell Bradley as President and General Manager of CNSide Diagnostics, LLC, a Plus Therapeutics subsidiary focused on advancing...

Welcome Michael Rosol, PhD!

Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical,...

$5.7 Million PSTV Funding

Plus Therapeutics Secures $5.7 Million in Funding to Advance Cancer Research #PSTV News: Plus Therapeutics has successfully closed a private placement with $3.7 million in upfront proceeds and received a $2.0 million advance payment from the Cancer Prevention and...

OSU: New ReSPECT-GBM Site

New Clinical Trial Site Now Enrolling – OSUCCC-James Joins ReSPECT-GBM! We are excited to announce that The Ohio State University Comprehensive Cancer Center – James (OSUCCC – James) has joined our ReSPECT-GBM Clinical Trial as a new investigation site, with Principal...